Metabolic research — early stage
SLU-PP-332 5 mg
An early-stage experimental ERR agonist compound studied in animal models of exercise-related metabolism. Preclinical only.
What it is
SLU-PP-332 is an experimental small-molecule oestrogen-related-receptor agonist described in academic publications. It is a laboratory research compound with no clinical development programme completed.
Mechanism being studied
Reported to activate ERR isoforms associated with mitochondrial and oxidative metabolism pathways in rodent studies.
Human evidence
There is no human clinical evidence. It has not been evaluated for safety or efficacy in people.
Safety considerations
No human safety data exists. Use in people is not supported by any evidence and is not appropriate outside authorised research. Safety information for this compound is incomplete outside of controlled settings. Reported considerations in the literature include injection-site reactions, unknown long-term effects, product-quality and sterility risks with unregistered preparations, and unpredictable interactions with existing medicines or conditions. Any consideration of use belongs with a registered healthcare professional who can assess the individual clinical picture.
Regulatory status
Research-only. Not approved anywhere for human use.
Certificate of analysis
Third-party analytical documentation for this compound is published for transparency and professional review. It confirms identity and purity of tested material only, and is not a marketing authorisation, a registration, or a recommendation for use.
View certificate (PDF)Key references
- Academic publications describing SLU-PP-332 in rodent models.
- PubMed-indexed ERR agonist literature.
References are provided as reading directions for professionals. They do not constitute endorsement of any use.
Information only — availability subject to applicable law, prescription/authorisation, and licensed healthcare/pharmacy channels. Nothing on this page is an offer to sell, and no dosing or self-administration guidance is provided.
South Africa — compliance notice
SAHPRA has publicly warned about unregistered peptide products being marketed to the South African public. In general, products intended to diagnose, treat, or otherwise alter bodily functions require registration or authorisation before they may lawfully be sold. ELLIVON BIOSCIENCES publishes reference information only and directs all clinical questions to registered healthcare professionals and licensed pharmacy channels.